CLOs on the Move

Q2 Solutions

www.q2labsolutions.com

 
Q² Solutions, a Quintiles Quest joint venture Launched in 2015, Q² Solutions (pronounced Q-squared) is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q² Solutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q² Solutions joint venture was formed by Quintiles and Quest Diagnostics, combining the best of each parent organizations clinical trials laboratory services capabilities.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Canton Potsdam Hospital

Canton Potsdam Hospital is a voluntary, private, not for profit, general, acute care community healthcare organization, providing health care to the people of St. Lawrence County, and to areas beyond for specialty services.

SNDL

Sundial believes in health, happiness and personal well-being. Our cannabis is carefully cultivated for modern consumers—people looking for a natural alternative that fits todays active lifestyles. We are a licensed cannabis producer based in Alberta. We combine tried-and-true heartland farming with innovative horticultural techniques to grow a select range of cannabis strains. Our focus is on consistency—a pure cannabis experience that our customers can trust and count on.

Organifi

Uniting the World through Health and Happiness.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.

MedCare Investment Funds

MedCare and its affiliated entities manage approximately $1 billion in assets, the substantial majority of which are related to the medical and healthcare services industry.